As the year 2023 comes to a close, it’s time to take a moment to reflect on what has been achieved during the year. This year at Forsante, we have had a particular emphasis on product development.
The development work for the new Clozapine and Diabetes services has continued, and these services will be certified according to the MDR (Medical Device Regulation) in the coming year. Like Forsante’s other services, these new services will significantly save time in healthcare. Forsante’s automation will reduce the time spent on routine tasks, and also assist in decision-making.
In the fall, we introduced an update to Forsante Anticoagulation, including several user-requested usability enhancements. One of the biggest advantages of our service is automatic medication calculation and communication of dosage to the patient. The treatment process for patients in good treatment balance can be almost entirely automated. Automation is at the core of what we do at Forsante, and these updates to the Anticoagulation service allow for even better utilization of this feature.
Our partners and customers have recognized Forsante’s long-term commitment to continuous development of healthcare treatment processes. We recently won the procurement process conducted by Istekki Ltd, regarding all Forsante services. Within the framework of this agreement, Finnish healthcare regions are able to adopt Forsante’s services without undergoing new competitive bidding or procurement procedures.
We would like to thank all our customers and partners for the past year. We wish everyone a hopeful New Year 2024!
